To test the hypothesis that antituberculous drug disposition is altered in patients with AIDS, we studied the steady-state pharmacokinetics of isoniazid (300 mg/d), rifampin (600 mg/d), and pyrazinamide (1,500 mg/d) in 29 adults (14 patients infected with human immunodeficiency virus [HIV] and 15 non-HIV-infected patients) with tuberculosis in Nairobi, Kenya. Intestinal integrity was assessed with xylose. Neither HIV infection nor diarrhea accounted for the interpatient variability in the area-under-the-plasma concentration vs. time curve (AUC), the maximum concentration, or the terminal half-life (t 1/2 ) of isoniazid, rifampin, and pyrazinamide. No significant association between HIV infection or diarrhea and pharmacokinetics was seen for any of the compounds. In addition, neither the AUC nor the t 1/2 of any of these drugs reflected interpatient differences in CD4 lymphocyte counts. Xylose absorption was uniformly low. We did not demonstrate that HIV infection, diarrhea, or CD4 lymphocyte counts contributed significantly to the variability in pharmacokinetics of isoniazid, rifampin, and pyrazinamide in TB patients in Nairobi.
Although most HIV-infected patients with tuberculosis (TB)
isting dose-response data and serum-concentration response data [14 -17] suggest that reduced bioavailability of antimycorespond well to rifampin-based antimycobacterial drug regimens [1 -8] , recent reports suggest that malabsorption of antibacterial drugs could have serious consequences for HIVinfected patients with TB, such as delayed or incomplete remycobacterial drugs occurs in selected HIV-infected patients with TB -particularly those with advanced HIV infection sponse to treatment or selection for drug resistance. Our objectives were to study the pharmacokinetics of three [9 -13] . In case reports involving a total of 34 patients with AIDS and TB and in two case series (one involving 26 patients antimycobacterial drugs -isoniazid, rifampin, and pyrazinamide -in HIV-infected and non-HIV-infected patients with with AIDS and TB and another involving 15 patients with AIDS and disseminated Mycobacterium avium complex dis-TB to determine if HIV infection alters the bioavailability of these drugs and to determine whether altered bioavailability is ease), malabsorption of antimycobacterial drugs was suggested by much-reduced serum levels, which were measured 2 hours related to the stage of HIV infection, as measured by CD4 lymphocyte counts, and the presence or absence of diarrhea. after oral administration of the drugs [9 -13] . The timing of such screening relative to dosing was based on data for non-
The relationship between the absorption of antituberculous drugs and that of xylose, a sugar commonly used to measure HIV-infected patients, and the possibility of delayed absorption was not taken into account.
intestinal integrity, was also evaluated. Serial measurements allowing determination of standard pharmacokinetic parameters (area-under-the-plasma concentraMethods tion vs. time curve [AUC] , the maximum plasma concentration Over a 1-year period beginning on 1 November 1994, all [C max ], and time to maximum plasma concentration [T max ]) are adults (i.e., patients §17 years of age) who presented to the more accurate measures of drug bioavailability but have been Infectious Disease Hospital in Nairobi, Kenya, with sputum reported for only one HIV-infected patient with TB [11] . Exsmear -positive pulmonary TB and who were not prisoners were evaluated prospectively for entry into a study of antimycobacterial-drug pharmacokinetics. Patients were required to All patients meeting these criteria were admitted to the hospiAll assays had previously been validated and approved by Health Canada (Ottawa, Ontario, Canada) and were specific tal, and baseline demographic, clinical, and laboratory data were collected. Oral first-line antimycobacterial drug therapy for the drugs of interest in the presence of nonantimycobacterial drugs used by the patients. In addition, all assays complied with isoniazid (300 mg/d), rifampin (600 mg/d [or 450 mg/d if the patient weighed less than 45 kg]), ethambutol (800 with the College of American Pathologists guidelines for reproducibility and quality control. mg/d), and pyrazinamide (1,500 mg/d) was prescribed. Steadystate pharmacokinetic studies of isoniazid, rifampin, and pyraXylose was measured in serum drawn at time 0 (1 hour after xylose ingestion) by a colorimetric method [23] . On the zinamide were performed on day 14.
Demographic, clinical and laboratory data. For each patient, assumption that xylose does not occur naturally and in an effort to minimize sampling blood loss, baseline xylose levels were the age at diagnosis of TB and sex were recorded. Height (m) and weight (kg) were measured, and the body mass index not measured. Pharmacokinetic data analysis. Appropriate ''model-inde-(kg/m 2 ) was calculated. Note was made of any drugs other than antimycobacterial drugs being administered, and the presence pendent'' pharmacokinetic parameters were determined from the plasma concentration-time profiles for each participant or absence of diarrhea (three or more unformed stools per day for §3 days) and wasting (involuntary weight loss of ú10% drug. The highest plasma drug concentration observed over the dose interval at steady-state (C max ) and the time at which it of baseline body weight) was also noted.
Stool samples were cultured for bacterial enteropathogens occurred (T max ) were determined. The AUC was determined over a dosing interval by using the trapezoidal rule. The termiand examined for ova and parasites (by means of wet mount, trichrome staining, and modified acid-fast staining for crypnal elimination rate constant was calculated by least squares regression of the natural logarithm of the plasma drug concentosporidia) at the Kemri Microbiology Laboratories, Nairobi. Testing for antibodies to HIV (two independent ELISAs were tration vs. time for the terminal linear portion. The t 1/2 was calculated by dividing the terminal disposition rate constant performed, with pretest and posttest counseling) and a lymphocyte subset analysis (Becton Dickinson, Mississauga, Ontario, into 0.693 [24] . The AUC and C max were normalized to a body weight of 70 kg and to doses of 300 mg for isoniazid, 600 mg Canada) were performed at the World Health Organization Collaborative Centre for STD and HIV Control, Nairobi.
for rifampin, and 1,500 mg for pyrazinamide. The code was broken after completion of the analytical and pharmacokinetic Pharmacokinetic protocol. Patients were not allowed to receive anything by mouth after midnight of day 13, and on analyses. Analysis of variance (ANOVA) (SYSTAT; SYSTAT Inc., day 14, heparin locks were established. At 0700, each patient was given 5 g of xylose in 100 mL of water. At 0800 (time Evanston, IL [25] ) was used to assess the potential for HIV infection, diarrhea, or an association between them to account 0), antimycobacterial drugs were administered with 150 mL of water while the patients were in upright positions. Patients for interpatient variability in AUC, C max , and t 1/2 . ANOVA was also used to assess the potential for CD4 lymphocyte counts were not permitted to eat or assume a completely recumbent position for 2 hours after ingestion of the drugs. Blood samples to account for interpatient variability in AUC and t 1/2 [25] . The influence of acetylator status on AUC and t 1/2 of isoniazid was were obtained just before drug ingestion at time 0 (trough) and at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 4 hours, included in the ANOVA model. The Bonferroni correction factor was applied to control for the type I error rate, resulting 6 hours, 8 hours, and 12 hours after drug ingestion. Ascorbic acid was added to the blood tubes before the specimens were in a P value of .05 indicating significance. The x 2 test and the Student's t test were applied to determine the significance collected to prevent oxidation of rifampin. Within 1 hour of collection, the blood samples were centrifuged, and the plasma between discrete and continuous variables, respectively, with use of SYSTAT [25] . Differences (P õ .05) for two-tailed was stored at 070ЊC.
Pharmaceutical assays and assay of xylose. All samples tests were considered significant. remained frozen until assay. Plasma levels of the three antimycobacterial drugs (isoniazid, rifampin, and pyrazinamide) were measured in the Clinical Investigation Unit of the Ottawa Results General Hospital, Ottawa, Ontario, Canada. Assays were performed in a blinded fashion with use of high-performance liqOver the 1-year study period, 465 patients with sputum smear -positive pulmonary TB presented to the Infectious Disuid chromatography (HPLC).
The HPLC method used to measure levels of isoniazid ease Hospital. Of these patients, 30 adults met the study entry criteria and were admitted to the hospital for baseline data and its acetyl metabolite was that described by Hutchings et al. [18] and modified by Gallicano et al. [19] . Patients were collection and administration of antimycobacterial drugs. The pharmacokinetics of the drugs could not be studied in one classified as fast acetylators on the basis of an isoniazid t 1/2 (terminal half-life) of õ130 minutes [20] . The HPLC patient who died while receiving treatment. The baseline demographic, clinical, and laboratory data on the remaining 29 paassays used to measure levels of rifampin and pyrazinamide were those described by Swart and Papgis [21] , and Brouard tients (14 HIV-infected patients and 15 non-HIV-infected patients) are shown in table 1. et al. [22] , respectively.
/ 9c33$$jy40
06-10-97 10:39:53 cidal UC: CID T lymphocyte subset analyses were not performed for eight HIV infected). ANOVA showed no association of acetylator status with any pharmacokinetic parameters. As expected, the effects of patients (three, HIV-infected, and five, non-HIV-infected). HIV-infected and noninfected patients did not differ signifiacetylator status were significant for the AUC and t were not significantly different for HIV-infected patients than for non-HIV-infected patients or for those with or without Three patients were taking nonantimycobacterial drugs; one non-HIV-infected patient was taking indomethacin, and andiarrhea. In addition, no significant association between the presence of HIV or diarrhea and pharmacokinetic properties other was taking trimethoprim-sulfamethoxazole; one HIVinfected patient was taking amoxicillin, metronidazole, and was seen for any of the compounds. The nonnormalized C max for isoniazid was õ3 mg/L in 24 (89%) of 27 patients; for N-butylscopolammonium bromide (Buscopan).
Standard doses of antimycobacterial drugs were administered to rifampin, õ8 mg/L in 26 (90%) of 29 patients; and for pyrazinamide, õ30 mg/L in 2 (8%) of 26 patients. all but nine patients (four, HIV-infected; five, non-HIV-infected). These patients weighed õ45 kg at baseline and thus received 450
The t 1/2 data supported the conclusion that drug disposition was unaffected by HIV infection or diarrhea; there was no mg of rifampin. The plasma concentration-time data allowed for a complete determination of the pharmacokinetics of isoniazid significant difference in the t 1/2 (hours) of isoniazid, rifampin, or pyrazinamide in HIV-infected patients vs. non-HIV-infected in 25 patients, rifampin in 29 patients, and pyrazinamide in 26 patients.
patients or in patients with or without diarrhea. No association with HIV infection or diarrhea was reflected in the t 1/2 data for Determinations of isoniazid pharmacokinetics were incomplete for two patients. For isoniazid, the acetylator status was deterisoniazid, rifampin, or pyrazinamide. The mean time ({SD) to achieve C max (T max ) was also not mined in 25 of the 29 patients; incomplete pharmacokinetic data precluded acetylator phenotyping in four patients. There were five significantly different in HIV-infected patients (isoniazid, 2.3 { 1.6 hours; rifampin, 2.4 { 1.5 hours; and pyrazinamide, fast acylators (four, HIV infected) and 20 slow acetylators (eight, / 9c33$$jy40 06-10-97 10:39:53 cidal UC: CID NOTE. Data (mean value { SD) were normalized to a 300-mg dose of isoniazid, a 600-mg dose of rifampin, a 1,500-mg dose of pyrazinamide, and 70 kg of body weight. AUC Å area under the plasma concentration vs. time curve; C max Å maximum concentration; t 1/2 Å terminal half-life.
{ 1.5 hours) than in non-HIV-infected patients (isoniazid,
complete the assay. After correction for body surface area, we found that all but four patients had xylose levels of õ0. Centre, Winnipeg, Manitoba, Canada). the AUC nor the t 1/2 of isoniazid, rifampin, and pyrazinamide was affected by interpatient differences in CD4 cell counts. Discussion Xylose was measured in the trough blood samples of 20 patients (12 HIV-infected and eight non-HIV-infected). For Provided HIV-infected patients with TB are treated with a rifampin-based instead of a thiacetazone-based regimen (the nine patients, there was an insufficient amount of plasma to latter has been associated with a higher relapse rate), response tion -an approximation of peak concentrations or C max -are often well below the expected normal range (i.e., isoniazid, to antimycobacterial therapy is generally good and comparable to that of non-HIV-infected patients [1 -8] . In a joint statement 3 -5 mg/L; rifampin, 8 -24 mg/L; and pyrazinamide, 30 -40 mg/L) [27, 28] . These low levels were measured in patients by members of the American Thoracic Society and investigators at the Centers for Disease Control and Prevention on the who were determined to have AIDS on the basis of the pre-1993 definition (i.e., they had advanced HIV infection assotreatment of TB and TB infection in adults and children, a three-drug (initial phase), 6-month regimen for both HIV-inciated with either extrapulmonary TB or disseminated M. avium complex, or they had TB plus another AIDS-defining illness). fected and non-HIV-infected persons with drug-susceptible disease is recommended [26] .
In 1993, the surveillance case definition of AIDS was modified to include pulmonary TB [29, 30] . Nevertheless, it appears that in some HIV-infected patients with TB (particularly those with advanced HIV infection who Whether such low ''peak'' drug levels truly represent a low C max and AUC that threaten the adequacy of standard therapy malabsorb their antimycobacterial drugs), concentrations of many drugs including isoniazid, rifampin, and, to a lesser exand whether low levels correlate with the degree of immunosuppression (CD4 cell counts) or the presence of diarrhea is untent, pyrazinamide in blood drawn 2 hours after oral inges- On the other hand, the values for pyrazinamide were similar to those cited in the literature on non-HIV-infected patients case reports [11] suggest that low concentrations may indeed lead to therapeutic failures and/or drug resistance. Pharmacokinetic with AIDS [33] and were consistent with many of the values cited in recent TB-AIDS case reports where the absorption of studies in HIV-infected patients from North America without TB suggest that malabsorption of antimycobacterial drugs increases isoniazid, rifampin, and other antituberculous drugs appeared to be reduced, whereas pyrazinamide absorption was relatively as HIV disease becomes more advanced (as determined by lower CD4 cell counts and the presence of diarrhea) [31] .
well preserved. Why isoniazid and rifampin bioavailability was reduced in In the present study, we measured the pharmacokinetic parameters of orally administered isoniazid, rifampin, and pyrazinamide our non-HIV-infected TB patients as well as in our HIVinfected TB patients is unclear. Significantly reduced antituberin 29 patients with TB, 14 of whom were infected with HIV and 15 of whom were not infected with the virus. This study was culous drug levels have not been reported in other non-HIVinfected patients with TB. We speculate that population differperformed in Africa, where as many as 90% of patients with AIDS are reported to have gastrointestinal dysfunction [32] . We ences -our patients were East African, and almost all were cachectic (93% of our HIV-infected patients and 80% of our found that neither diarrhea nor HIV accounted for the interpatient variability in the AUC, C max , or t 1/2 of isoniazid, rifampin, and non-HIV-infected patients had severe wasting) -resulted in the across-the-board reduced bioavailability of isoniazid and pyrazinamide. Furthermore, no significant association between the presence of HIV or diarrhea and pharmacokinetics was seen rifampin. Perhaps severe wasting is a predictor of drug malabsorption in both HIV-infected and noninfected patients. Wastfor any of the compounds, and neither the variability in bioavailability (AUC) nor the variability in elimination (t 1/2 ) of isoniazid, ing or malnutrition sufficient to cause small-bowel edema, villous atrophy, or bacterial overgrowth might be expected to rifampin, and pyrazinamide was explained by interpatient differences in CD4 cell counts. result in malabsorption [34] .
We have no reason to think that the isoniazid and rifampin Although four antimycobacterial drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) were administered to each paformulations were substandard, and although the stability of rifampin may be problematic in the tropics, there is no reason tient (initial coverage allowed for the possibility of drug resistance), our analysis was limited to the study of isoniazid, rifamto question the stability of isoniazid. The lack of any effect of CD4 cell counts or diarrhea on drug bioavailability within our pin, and pyrazinamide, as a parenteral alternative is available for ethambutol (streptomycin), and we wished to keep sampling HIV-infected group (as has been reported for HIV-infected North American patients without TB [31] ) may have been blood loss at a minimum.
Because testing for antibodies to HIV is not routinely perbecause of the small number of patients or the overriding influence of cachexia. formed for TB patients in Nairobi and because most TB patients who presented to the hospital were excluded from the study Our xylose measurements suggest that a component of altered absorption may indeed have contributed to our results; either because they were prisoners or because they refused to consent to the necessary 2-week hospitalization, it is possible the levels were low in all patients (12 HIV-infected and eight non-HIV-infected patients) tested. A low xylose level indicates that our study included a more debilitated subset of both HIVinfected and non-HIV-infected patients.
poor mucosal absorption or contamination of the jejunum by bacteria that metabolize the sugar before it can be absorbed. Variation in the rate of elimination of isoniazid is a function of metabolism and is known to have a bimodal distribution, Interactions between the four antimycobacterial drugs [27, 35, 36] , the measurement of pharmacokinetic parameters at which is primarily based on an individual's genetically controlled acetylator phenotype [28] . As expected, the effects of steady-state (rifampin induces its own hepatic metabolism, and the C max and t 1/2 of rifampin decline over the first 1 -2 weeks acetylator status were significant for the AUC and t 1/2 , with shorter half-lives and lower AUC values observed in fast acylaof therapy) [37] , and the use of HPLC assays, as opposed to bioassays (which may measure metabolites as well as parent tors than in slow acetylators. However, there was no association of acetylator status with any of the pharmacokinetic parameters compound) [23] , were other factors that may have contributed to our finding of reduced bioavailability of isoniazid and rifammeasured.
When we compared the absolute values of the observed pin, as compared with some, but not all, values cited in the literature [28, 33] . However, because all 29 patients underwent (C max , T max ) and calculated (AUC, t 1/2 ) pharmacokinetic parameters for isoniazid, rifampin, and pyrazinamide with the values the same preparation and received the same treatment (nonantimycobacterial drugs administered to three of the patients are cited in the literature on non-HIV-infected patients with TB [33] , we noted across-the-board reduced bioavailability of isonot known to influence the absorption or metabolism of isoniazid, rifampin, or pyrazinamide), our comparison of pharmaconiazid and, to a lesser extent, rifampin. This was true even when the raw, nonnormalized values were considered: e.g., kinetic parameters between groups remains valid. Even though our patients' severe wasting may have reduced the mean nonnormalized C max ({SD) values for isoniazid and rifampin were 1.81 { .88 mg/L and 5.16 { 3.67 mg/L, respecthe bioavailability of isoniazid and rifampin, the fact that peak serum concentrations were still well above the MICs for Mycotively (values were normalized to 70 kg of body weight for purposes of comparing the pharmacokinetics).
bacterium tuberculosis (i.e., £0.1 mg/L for isoniazid and £0.5
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